Unique circulating microRNA profiles in epidemic Kaposi's sarcoma
Authors:
- Haruna MuwongeHMHaruna Muwonge
- Hassan KasujjaHKHassan Kasujja
- Nixon NiyonzimaNNNixon Niyonzima
- Carolyne AtugonzaCACarolyne Atugonza
- Josephine KasoloJKJosephine Kasolo
- Allan LugaajjuALAllan Lugaajju
- Joshua NfambiJNJoshua Nfambi
- Sembajwe Larry FredSFSembajwe Larry Fred
- Ali Moses DamaniADAli Moses Damani
- Ivan KimuliIKIvan Kimuli
- Robert ZavugaRZRobert Zavuga
- Faith NakazziFNFaith Nakazzi
Open Access
- 10 April 2022
- journal article
- research article
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 7 (2) , 114-122
Abstract
Human herpesvirus 8 (HHV-8) causes Kaposi's sarcoma (KS). Kaposi sarcoma in HIV/AIDS patients is referred to as epidemic KS and is the most common HIV-related malignancy worldwide. The lack of a diagnostic assay to detect latent and early-stage disease has increased disease morbidity and mortality. Serum miRNAs have previously been used as potential biomarkers of normal physiology and disease. In the current study, we profiled unique serum miRNAs in patients with epidemic KS to generate baseline data to aid in developing a miRNA-based noninvasive biomarker assay for epidemic KS. This was a comparative cross-sectional study involving 27 patients with epidemic KS and 27 HIV-positive adults with no prior diagnosis or clinical manifestation of KS. DNA and RNA were isolated from blood and serum collected from study participants. Nested PCR for circulating HHV-8 DNA was performed on the isolated DNA, whereas miRNA library preparation and sequencing for circulating miRNA were performed on the RNA samples. The miRge2 pipeline and EdgeR were used to analyse the sequencing data. Fifteen out of the 27 epidemic KS-positive subjects (55.6%) tested positive for HHV-8 DNA, whereas only 3 (11.1%) out of the 27 HIV-positive, KS-negative subjects tested positive for HHV-8 DNA. Additionally, we found a unique miRNA expression signature in 49 circulating miRNAs in epidemic KS subjects compared to subjects with no epidemic KS, with 41 miRNAs upregulated and 8 miRNAs downregulated. Subjects with latent KS infection had a differential upregulation of circulating miR-193a compared to HIV-positive, KS-negative subjects for whom circulating HHV-8 DNA was not detected. Further analysis of serum from epidemic KS patients revealed a miRNA signature according to KS tumor status and time since first HIV diagnosis. This study reveals unique circulating miRNA profiles in the serum of patients with epidemic KS versus HIV-infected subjects with no KS, as well as in subjects with latent KS. Many of the dysregulated miRNAs in epidemic KS patients were previously reported to have crucial roles in KS infection and latency, highlighting their promising roles as potential biomarkers of latent or active KS infection.Keywords
All Related Versions
This publication has 38 references indexed in Scilit:
- Circulating miRNAs: cell–cell communication function?Frontiers in Genetics, 2013
- A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus Latency and ReactivationAdvances in Virology, 2011
- Gender Differences in Clinical Presentation and Outcomes of Epidemic Kaposi Sarcoma in UgandaPLOS ONE, 2010
- Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146aOncogene, 2009
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- MicroRNA Expression, Survival, and Response to Interferon in Liver CancerNew England Journal of Medicine, 2009
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2005
- How does HAART lead to the resolution of Kaposi's sarcoma?Journal of Antimicrobial Chemotherapy, 2003